Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

Baird RD, van Rossum AG, Oliveira M, Beelen KJ, Gao M, Schrier M, Mandjes IA, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, Van Tinteren H, Callari M, Beddowes E, Pérez-Garcia J, Rosing H, Platte E, Nederlof PM, Schot M, de Vries Schultink AH, Bernards R, Saura C, Gallagher WM, Cortés J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Aug 22. pii: clincanres.0508.2019. doi: 10.1158/1078-0432.CCR-19-0508. [Epub ahead of print]

PMID:
31439579
2.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121723. doi: 10.1016/j.jchromb.2019.121723. Epub 2019 Jul 18.

PMID:
31352204
3.

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.

Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.

Mol Pharm. 2019 Sep 3;16(9):3842-3852. doi: 10.1021/acs.molpharmaceut.9b00475. Epub 2019 Aug 5.

PMID:
31329454
4.

P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.

Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32568. [Epub ahead of print]

PMID:
31304590
5.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 10;174:561-566. doi: 10.1016/j.jpba.2019.06.034. Epub 2019 Jun 24.

PMID:
31255856
6.

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM.

Clin Genitourin Cancer. 2019 May 30. pii: S1558-7673(19)30176-4. doi: 10.1016/j.clgc.2019.05.026. [Epub ahead of print] No abstract available.

PMID:
31248829
7.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Sep 15;25(18):5466-5474. doi: 10.1158/1078-0432.CCR-17-2299. Epub 2019 Jun 19.

PMID:
31217201
8.

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

van Nuland M, Rosing H, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2019 Jun 18:e4623. doi: 10.1002/bmc.4623. [Epub ahead of print] Review.

PMID:
31215049
9.

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.

Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH.

Anal Bioanal Chem. 2019 Aug;411(20):5331-5345. doi: 10.1007/s00216-019-01932-w. Epub 2019 Jun 17.

10.

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 5;173:169-175. doi: 10.1016/j.jpba.2019.05.037. Epub 2019 May 21.

PMID:
31146172
11.

Predictive Value of Microdose Pharmacokinetics.

van Nuland M, Rosing H, Huitema ADR, Beijnen JH.

Clin Pharmacokinet. 2019 Apr 27. doi: 10.1007/s40262-019-00769-x. [Epub ahead of print] Review.

PMID:
31030372
12.

LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.

van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Jun 5;170:161-168. doi: 10.1016/j.jpba.2019.03.043. Epub 2019 Mar 20.

PMID:
30925273
13.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.

PMID:
30754019
14.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 1;1106-1107:26-34. doi: 10.1016/j.jchromb.2019.01.001. Epub 2019 Jan 3.

15.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2019 Apr;17(2):e383-e386. doi: 10.1016/j.clgc.2018.12.004. Epub 2018 Dec 19. No abstract available.

16.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
17.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
18.
19.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
20.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2.

PMID:
30279580
21.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
22.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

23.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

24.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Nov;172(1):143-150. doi: 10.1007/s10549-018-4886-8. Epub 2018 Jul 13.

25.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4.

PMID:
29974200
26.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.

PMID:
29883879
27.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.

28.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.

PMID:
29430582
29.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Mar 20;151:25-31. doi: 10.1016/j.jpba.2017.12.048. Epub 2017 Dec 26.

PMID:
29294409
30.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
31.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

32.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815
33.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Biomed Anal. 2018 Jan 30;148:259-264. doi: 10.1016/j.jpba.2017.10.009. Epub 2017 Oct 18.

PMID:
29059615
34.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:119-124. doi: 10.1016/j.jchromb.2017.10.033. Epub 2017 Oct 16.

PMID:
29059586
35.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46. doi: 10.1007/s00280-017-3455-x. Epub 2017 Oct 17. Erratum in: Cancer Chemother Pharmacol. 2017 Nov 27;:.

36.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
37.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.

Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.

38.

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.

Henricks LM, Siemerink EJM, Rosing H, Meijer J, Goorden SMI, Polstra AM, Zoetekouw L, Cats A, Schellens JHM, van Kuilenburg ABP.

Int J Cancer. 2018 Jan 15;142(2):424-430. doi: 10.1002/ijc.31065. Epub 2017 Sep 30.

39.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

40.

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

van Andel L, Rosing H, Fudio S, Avilés P, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2017 Oct 25;145:137-143. doi: 10.1016/j.jpba.2017.06.013. Epub 2017 Jun 21.

PMID:
28662481
41.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.

van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Ther Drug Monit. 2017 Jun;39(3):243-251. doi: 10.1097/FTD.0000000000000387.

PMID:
28490047
42.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

43.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2. Epub 2017 Mar 16.

44.

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

Nijenhuis CM, Lucas L, Rosing H, Huitema ADR, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Aug;35(4):478-490. doi: 10.1007/s10637-017-0428-1. Epub 2017 Jan 31.

PMID:
28138829
45.

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.

PMID:
28111728
46.

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2017 Apr;39(2):132-137. doi: 10.1097/FTD.0000000000000372.

PMID:
28045782
47.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip AE, Kiers KC, Rosing H, Schellens JHM, Beijnen JH, Dorlo TPC.

J Pharm Biomed Anal. 2017 Feb 20;135:160-166. doi: 10.1016/j.jpba.2016.12.012. Epub 2016 Dec 9.

PMID:
28033553
48.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:14-21. doi: 10.1016/j.jchromb.2016.11.020. Epub 2016 Nov 19.

PMID:
27898364
49.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2016 Dec;38(6):649-656.

PMID:
27749781
50.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-398. doi: 10.1016/j.jchromb.2016.09.012. Epub 2016 Sep 11. No abstract available.

PMID:
27639128

Supplemental Content

Loading ...
Support Center